Neboglamine hydrochloride
Based on 1 Customer Validation
Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research.
For research use only. We do not sell to patients.
- Purity: 97.02%
- CAS No.: 2759182-59-5
- Formula: C13H25ClN2O3
- Molecular Weight:292.80
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neuroprotective Compound Library
HY-L070
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Antidepressant Compound Library
HY-L108
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
All iGluR Isoforms
More
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats[1]
-
Dosage:20 mg/kg
-
Administration:Subcutaneous injection
-
Result:Increased neuronal activity in brain regions, prefrontal cortex (PFCX) from 38.5 to 121.3, nucleus accumbens (NAc) from 14.5 to 69.1 and lateral septal nucleus (LSN) from 16.2 to 73.1 but no effect on dorsolateral striatum (DL-STR) compared to the control group.
Significantly inhibited phencyclidine-induced hypermobility.
-
Animal Model:Male Wistar rats[1]
-
Dosage:0.3 mg/kg, 3 mg/kg, 30 mg/kg
-
Administration:Oral administration
-
Result:Reduced frequency of PCP-induced hypermobility and stereotyped behaviour in a dose-dependent manner and the dose inhibited stereotyped behaviour (0.3 mg/kg) was lower than the dose inhibited motor activity (3 mg/kg).
Chemical Information
-
CAS No. 2759182-59-5
-
Appearance Solid
-
Molecular Weight 292.80
-
Formula C13H25ClN2O3
-
Color White to off-white
-
SMILES
OC(CC[C@H](N)C(NC1CCC(C)(CC1)C)=O)=O.Cl
-
Synonyms
CR-2249 hydrochloride; XY-2401 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (341.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.54 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.54 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4153 mL | 17.0765 mL | 34.1530 mL | 85.3825 mL |
| 5 mM | 0.6831 mL | 3.4153 mL | 6.8306 mL | 17.0765 mL | |
| 10 mM | 0.3415 mL | 1.7077 mL | 3.4153 mL | 8.5383 mL | |
| 15 mM | 0.2277 mL | 1.1384 mL | 2.2769 mL | 5.6922 mL | |
| 20 mM | 0.1708 mL | 0.8538 mL | 1.7077 mL | 4.2691 mL | |
| 25 mM | 0.1366 mL | 0.6831 mL | 1.3661 mL | 3.4153 mL | |
| 30 mM | 0.1138 mL | 0.5692 mL | 1.1384 mL | 2.8461 mL | |
| 40 mM | 0.0854 mL | 0.4269 mL | 0.8538 mL | 2.1346 mL | |
| 50 mM | 0.0683 mL | 0.3415 mL | 0.6831 mL | 1.7077 mL | |
| 60 mM | 0.0569 mL | 0.2846 mL | 0.5692 mL | 1.4230 mL | |
| 80 mM | 0.0427 mL | 0.2135 mL | 0.4269 mL | 1.0673 mL | |
| 100 mM | 0.0342 mL | 0.1708 mL | 0.3415 mL | 0.8538 mL |
Neboglamine hydrochloride Related Classifications
HY-114753A Related Classifications
Powered by Bioz